
Calliditas Therapeutics AB presented additional analyses from its 2-year Phase 3 NeflgArd trial of Nefecon at the ISN World Congress of Nephrology. The data highlighted Nefecon's consistent improvement of eGFR over 2 years in IgA nephropathy patients, regardless of baseline UPCR or racial and ethnic backgrounds. The analyses also demonstrated Nefecon's efficacy in reducing UPCR, delaying kidney function decline, and maintaining quality of life across diverse patient populations.
Like
Save
Share